当前位置: 首页 >> 检索结果
121. Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta-analysis.
作者: Luz Viale.;John Allotey.;Fiona Cheong-See.;David Arroyo-Manzano.;Dougall Mccorry.;Manny Bagary.;Luciano Mignini.;Khalid S Khan.;Javier Zamora.;Shakila Thangaratinam.; .
来源: Lancet. 2015年386卷10006期1845-52页
Antenatal care of women with epilepsy is varied. The association of epilepsy and antiepileptic drug exposure with pregnancy outcomes needs to be quantified to guide management. We did a systematic review and meta-analysis to investigate the association between epilepsy and reproductive outcomes, with or without exposure to antiepileptic drugs.
122. Long working hours and risk of coronary heart disease and stroke: a systematic review and meta-analysis of published and unpublished data for 603,838 individuals.
作者: Mika Kivimäki.;Markus Jokela.;Solja T Nyberg.;Archana Singh-Manoux.;Eleonor I Fransson.;Lars Alfredsson.;Jakob B Bjorner.;Marianne Borritz.;Hermann Burr.;Annalisa Casini.;Els Clays.;Dirk De Bacquer.;Nico Dragano.;Raimund Erbel.;Goedele A Geuskens.;Mark Hamer.;Wendela E Hooftman.;Irene L Houtman.;Karl-Heinz Jöckel.;France Kittel.;Anders Knutsson.;Markku Koskenvuo.;Thorsten Lunau.;Ida E H Madsen.;Martin L Nielsen.;Maria Nordin.;Tuula Oksanen.;Jan H Pejtersen.;Jaana Pentti.;Reiner Rugulies.;Paula Salo.;Martin J Shipley.;Johannes Siegrist.;Andrew Steptoe.;Sakari B Suominen.;Töres Theorell.;Jussi Vahtera.;Peter J M Westerholm.;Hugo Westerlund.;Dermot O'Reilly.;Meena Kumari.;G David Batty.;Jane E Ferrie.;Marianna Virtanen.; .
来源: Lancet. 2015年386卷10005期1739-46页
Long working hours might increase the risk of cardiovascular disease, but prospective evidence is scarce, imprecise, and mostly limited to coronary heart disease. We aimed to assess long working hours as a risk factor for incident coronary heart disease and stroke.
123. Music as an aid for postoperative recovery in adults: a systematic review and meta-analysis.
Music is a non-invasive, safe, and inexpensive intervention that can be delivered easily and successfully. We did a systematic review and meta-analysis to assess whether music improves recovery after surgical procedures.
124. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.
125. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Bisphosphonates have profound effects on bone physiology, and could modify the process of metastasis. We undertook collaborative meta-analyses to clarify the risks and benefits of adjuvant bisphosphonate treatment in breast cancer.
126. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.
作者: Suetonia C Palmer.;Dimitris Mavridis.;Eliano Navarese.;Jonathan C Craig.;Marcello Tonelli.;Georgia Salanti.;Natasha Wiebe.;Marinella Ruospo.;David C Wheeler.;Giovanni F M Strippoli.
来源: Lancet. 2015年385卷9982期2047-56页
The comparative efficacy and safety of pharmacological agents to lower blood pressure in adults with diabetes and kidney disease remains controversial. We aimed to investigate the benefits and harms of blood pressure-lowering drugs in this population of patients.
127. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
作者: Jasvinder A Singh.;Chris Cameron.;Shahrzad Noorbaloochi.;Tyler Cullis.;Matthew Tucker.;Robin Christensen.;Elizabeth Tanjong Ghogomu.;Doug Coyle.;Tammy Clifford.;Peter Tugwell.;George A Wells.
来源: Lancet. 2015年386卷9990期258-65页
Serious infections are a major concern for patients considering treatments for rheumatoid arthritis. Evidence is inconsistent as to whether biological drugs are associated with an increased risk of serious infection compared with traditional disease-modifying antirheumatic drugs (DMARDs). We did a systematic review and meta-analysis of serious infections in patients treated with biological drugs compared with those treated with traditional DMARDs.
128. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials.
作者: Tullio Palmerini.;Umberto Benedetto.;Letizia Bacchi-Reggiani.;Diego Della Riva.;Giuseppe Biondi-Zoccai.;Fausto Feres.;Alexandre Abizaid.;Myeong-Ki Hong.;Byeong-Keuk Kim.;Yangsoo Jang.;Hyo-Soo Kim.;Kyung Woo Park.;Philippe Genereux.;Deepak L Bhatt.;Carlotta Orlandi.;Stefano De Servi.;Mario Petrou.;Claudio Rapezzi.;Gregg W Stone.
来源: Lancet. 2015年385卷9985期2371-82页
Despite recent studies, the optimum duration of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent placement remains uncertain. We performed a meta-analysis with several analytical approaches to investigate mortality and other clinical outcomes with different DAPT strategies.
129. International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology.
作者: Ravindra L Mehta.;Jorge Cerdá.;Emmanuel A Burdmann.;Marcello Tonelli.;Guillermo García-García.;Vivekanand Jha.;Paweena Susantitaphong.;Michael Rocco.;Raymond Vanholder.;Mehmet Sukru Sever.;Dinna Cruz.;Bertrand Jaber.;Norbert H Lameire.;Raúl Lombardi.;Andrew Lewington.;John Feehally.;Fredric Finkelstein.;Nathan Levin.;Neesh Pannu.;Bernadette Thomas.;Eliah Aronoff-Spencer.;Giuseppe Remuzzi.
来源: Lancet. 2015年385卷9987期2616-43页 130. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.
作者: J L Mega.;N O Stitziel.;J G Smith.;D I Chasman.;M Caulfield.;J J Devlin.;F Nordio.;C Hyde.;C P Cannon.;F Sacks.;N Poulter.;P Sever.;P M Ridker.;E Braunwald.;O Melander.;S Kathiresan.;M S Sabatine.
来源: Lancet. 2015年385卷9984期2264-2271页
Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy.
131. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.
Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk.
132. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.
作者: Joanna Dobson.;Richard J Whitley.;Stuart Pocock.;Arnold S Monto.
来源: Lancet. 2015年385卷9979期1729-1737页
Despite widespread use, questions remain about the efficacy of oseltamivir in the treatment of influenza. We aimed to do an individual patient data meta-analysis for all clinical trials comparing oseltamivir with placebo for treatment of seasonal influenza in adults regarding symptom alleviation, complications, and safety.
133. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
作者: .;Jordan Fulcher.;Rachel O'Connell.;Merryn Voysey.;Jonathan Emberson.;Lisa Blackwell.;Borislava Mihaylova.;John Simes.;Rory Collins.;Adrienne Kirby.;Helen Colhoun.;Eugene Braunwald.;John La Rosa.;T R Pedersen.;Andrew Tonkin.;Barry Davis.;Peter Sleight.;Maria Grazia Franzosi.;Colin Baigent.;Anthony Keech.
来源: Lancet. 2015年385卷9976期1397-405页
Whether statin therapy is as effective in women as in men is debated, especially for primary prevention. We undertook a meta-analysis of statin trials in the Cholesterol Treatment Trialists' (CTT) Collaboration database to compare the effects of statin therapy between women and men.
134. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials.
作者: .;A Ying.;H Arima.;S Czernichow.;M Woodward.;R Huxley.;F Turnbull.;V Perkovic.;B Neal.
来源: Lancet. 2015年385卷9971期867-74页
The cardiovascular benefits of blood pressure lowering in obese people compared with people of normal weight might depend on choice of drug. We compared the effects of blood pressure-lowering regimens on cardiovascular risk in groups of patients categorised by baseline body-mass index (BMI).
135. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis.
作者: Sammy Elmariah.;Laura Mauri.;Gheorghe Doros.;Benjamin Z Galper.;Kelly E O'Neill.;Philippe Gabriel Steg.;Dean J Kereiakes.;Robert W Yeh.
来源: Lancet. 2015年385卷9970期792-8页
Treatment with aspirin and a P2Y12 inhibitor is commonly used in patients with cardiovascular disorders. The overall effect of such treatment on all-cause mortality is unknown. In the Dual Antiplatelet Therapy (DAPT) Study, continuation of dual antiplatelet therapy beyond 12 months after coronary stenting was associated with an unexpected increase in non-cardiovascular death. In view of the potential public health importance of these findings, we aimed to assess the effect of extended duration dual antiplatelet therapy on mortality by doing a meta-analysis of all randomised, controlled trials of treatment duration in various cardiovascular disorders.
136. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
作者: Daniel I Swerdlow.;David Preiss.;Karoline B Kuchenbaecker.;Michael V Holmes.;Jorgen E L Engmann.;Tina Shah.;Reecha Sofat.;Stefan Stender.;Paul C D Johnson.;Robert A Scott.;Maarten Leusink.;Niek Verweij.;Stephen J Sharp.;Yiran Guo.;Claudia Giambartolomei.;Christina Chung.;Anne Peasey.;Antoinette Amuzu.;KaWah Li.;Jutta Palmen.;Philip Howard.;Jackie A Cooper.;Fotios Drenos.;Yun R Li.;Gordon Lowe.;John Gallacher.;Marlene C W Stewart.;Ioanna Tzoulaki.;Sarah G Buxbaum.;Daphne L van der A.;Nita G Forouhi.;N Charlotte Onland-Moret.;Yvonne T van der Schouw.;Renate B Schnabel.;Jaroslav A Hubacek.;Ruzena Kubinova.;Migle Baceviciene.;Abdonas Tamosiunas.;Andrzej Pajak.;Roman Topor-Madry.;Urszula Stepaniak.;Sofia Malyutina.;Damiano Baldassarre.;Bengt Sennblad.;Elena Tremoli.;Ulf de Faire.;Fabrizio Veglia.;Ian Ford.;J Wouter Jukema.;Rudi G J Westendorp.;Gert Jan de Borst.;Pim A de Jong.;Ale Algra.;Wilko Spiering.;Anke H Maitland-van der Zee.;Olaf H Klungel.;Anthonius de Boer.;Pieter A Doevendans.;Charles B Eaton.;Jennifer G Robinson.;David Duggan.; .; .; .;John Kjekshus.;John R Downs.;Antonio M Gotto.;Anthony C Keech.;Roberto Marchioli.;Gianni Tognoni.;Peter S Sever.;Neil R Poulter.;David D Waters.;Terje R Pedersen.;Pierre Amarenco.;Haruo Nakamura.;John J V McMurray.;James D Lewsey.;Daniel I Chasman.;Paul M Ridker.;Aldo P Maggioni.;Luigi Tavazzi.;Kausik K Ray.;Sreenivasa Rao Kondapally Seshasai.;JoAnn E Manson.;Jackie F Price.;Peter H Whincup.;Richard W Morris.;Debbie A Lawlor.;George Davey Smith.;Yoav Ben-Shlomo.;Pamela J Schreiner.;Myriam Fornage.;David S Siscovick.;Mary Cushman.;Meena Kumari.;Nick J Wareham.;W M Monique Verschuren.;Susan Redline.;Sanjay R Patel.;John C Whittaker.;Anders Hamsten.;Joseph A Delaney.;Caroline Dale.;Tom R Gaunt.;Andrew Wong.;Diana Kuh.;Rebecca Hardy.;Sekar Kathiresan.;Berta A Castillo.;Pim van der Harst.;Eric J Brunner.;Anne Tybjaerg-Hansen.;Michael G Marmot.;Ronald M Krauss.;Michael Tsai.;Josef Coresh.;Ronald C Hoogeveen.;Bruce M Psaty.;Leslie A Lange.;Hakon Hakonarson.;Frank Dudbridge.;Steve E Humphries.;Philippa J Talmud.;Mika Kivimäki.;Nicholas J Timpson.;Claudia Langenberg.;Folkert W Asselbergs.;Mikhail Voevoda.;Martin Bobak.;Hynek Pikhart.;James G Wilson.;Alex P Reiner.;Brendan J Keating.;Aroon D Hingorani.;Naveed Sattar.
来源: Lancet. 2015年385卷9965期351-61页
Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target.
137. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.
作者: Conrad Eng.;Caroline K Kramer.;Bernard Zinman.;Ravi Retnakaran.
来源: Lancet. 2014年384卷9961期2228-34页
Combination treatment with a glucagon-like peptide-1 (GLP-1) agonist and basal insulin has been proposed as a treatment strategy for type 2 diabetes that could provide robust glucose-lowering capability with low risk of hypoglycaemia or weight gain. We thus did a systematic review and meta-analysis of randomised controlled trials to assess the effect of this combination treatment on glycaemic control, hypoglycaemia, and weight gain in patients with type 2 diabetes.
138. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.
作者: Dipak Kotecha.;Jane Holmes.;Henry Krum.;Douglas G Altman.;Luis Manzano.;John G F Cleland.;Gregory Y H Lip.;Andrew J S Coats.;Bert Andersson.;Paulus Kirchhof.;Thomas G von Lueder.;Hans Wedel.;Giuseppe Rosano.;Marcelo C Shibata.;Alan Rigby.;Marcus D Flather.; .
来源: Lancet. 2014年384卷9961期2235-43页
Atrial fibrillation and heart failure often coexist, causing substantial cardiovascular morbidity and mortality. β blockers are indicated in patients with symptomatic heart failure with reduced ejection fraction; however, the efficacy of these drugs in patients with concomitant atrial fibrillation is uncertain. We therefore meta-analysed individual-patient data to assess the efficacy of β blockers in patients with heart failure and sinus rhythm compared with atrial fibrillation.
139. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.
Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention (PCI). We aimed to define the effects of a bivalirudin-based anticoagulation regimen compared with a heparin-based anticoagulation regimen on ischaemic and bleeding outcomes.
140. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data.
We aimed to investigate whether the benefits of blood pressure-lowering drugs are proportional to baseline cardiovascular risk, to establish whether absolute risk could be used to inform treatment decisions for blood pressure-lowering therapy, as is recommended for lipid-lowering therapy.
|